Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
REPEAT - Drilling at Swanson Gold Deposit Confirms Large-Scale Gold Discovery with 1.18 g/t Au over 255.04 metres and 1.65 g/t Au over 136.01 metres
